Eicosapentaenoic acid suppression of systemic inflammatory responses and inverse up‐regulation of 15‐deoxyΔ^12,14<scp>P</scp>rostaglandin <scp>J₂</scp> production

Abstract

Oral treatment with EPA can suppress immune/inflammatory responses in vivo via a suppression of upstream cytokine production resulting in a decreased fever response and indirectly reducing circulating levels of PGE2. EPA also enhances the production of the cytoprotective prostanoid 15d-PGJ2 indicating the therapeutic benefit of EPA.